Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-17 09:35 am Sale |
2025-03-31 | 13G | Celldex Therapeutics, Inc. CLDX |
BLACKROCK INC BLK |
4,819,293 7.300% |
-661,377 (-12.07%) |
Filing History |
| 2025-04-10 4:05 pm Purchase |
2025-04-03 | 13G | Celldex Therapeutics, Inc. CLDX |
Commodore Capital LP | 3,350,000 5.000% |
3,350,000 (New Position) |
Filing History |
| 2025-02-14 5:16 pm Purchase |
2024-12-31 | 13G | Celldex Therapeutics, Inc. CLDX |
Kynam Capital Management, LP | 5,064,207 7.630% |
2,058,303 (+68.48%) |
Filing History |
| 2025-02-14 09:44 am Purchase |
2024-12-31 | 13G | Celldex Therapeutics, Inc. CLDX |
PRICE T ROWE ASSOCIATES INC | 3,557,136 5.400% |
3,557,136 (New Position) |
Filing History |
| 2025-02-12 09:28 am Sale |
2024-12-31 | 13G | Celldex Therapeutics, Inc. CLDX |
FMR CORP | 4,857,668 7.300% |
-1,166,748 (-19.37%) |
Filing History |
| 2025-02-05 1:23 pm Purchase |
2024-12-31 | 13G | Celldex Therapeutics, Inc. CLDX |
BLACKROCK INC BLK |
5,480,670 8.300% |
1,804,978 (+49.11%) |
Filing History |
| 2024-11-14 7:47 pm Sale |
2024-09-30 | 13G | Celldex Therapeutics, Inc. CLDX |
Point72 Asset Management, L.P. | 1,684,032 2.500% |
-1,072,090 (-38.90%) |
Filing History |
| 2024-11-14 12:18 pm Sale |
2024-09-30 | 13G | Celldex Therapeutics, Inc. CLDX |
Eventide Asset Management, LLC | 3,332,005 5.030% |
-298,008 (-8.21%) |
Filing History |
| 2024-11-14 06:12 am Sale |
2024-09-30 | 13G | Celldex Therapeutics, Inc. CLDX |
RTW Investments, LP | 0 0.000% |
-3,463,201 (Position Closed) |
Filing History |
| 2024-11-13 6:00 pm Sale |
2024-09-30 | 13G | Celldex Therapeutics, Inc. CLDX |
Polar Capital Holdings Plc | 2,711,163 4.090% |
-424,708 (-13.54%) |
Filing History |
| 2024-11-12 09:55 am Sale |
2024-11-08 | 13G | Celldex Therapeutics, Inc. CLDX |
FMR CORP | 6,024,416 9.088% |
-1,025,993 (-14.55%) |
Filing History |
| 2024-11-08 10:52 am Purchase |
2024-09-30 | 13G | Celldex Therapeutics, Inc. CLDX |
WELLINGTON MANAGEMENT CO LLP | 9,243,599 13.940% |
2,767,038 (+42.72%) |
Filing History |
| 2024-02-14 4:17 pm Sale |
2023-12-31 | 13G | Celldex Therapeutics, Inc. CLDX |
Point72 Asset Management, L.P. | 2,756,122 5.000% |
-866,014 (-23.91%) |
Filing History |
| 2024-02-14 12:52 pm Purchase |
2023-12-31 | 13G | Celldex Therapeutics, Inc. CLDX |
Kynam Capital Management, LP | 3,005,904 5.500% |
3,005,904 (New Position) |
Filing History |
| 2024-02-14 11:48 am Purchase |
2023-12-31 | 13G | Celldex Therapeutics, Inc. CLDX |
Eventide Asset Management, LLC | 3,630,013 6.640% |
3,630,013 (New Position) |
Filing History |
| 2024-02-14 07:38 am Purchase |
2023-12-31 | 13G | Celldex Therapeutics, Inc. CLDX |
RTW Investments, LP | 3,463,201 6.300% |
378,986 (+12.29%) |
Filing History |
| 2024-02-13 5:00 pm Purchase |
2023-12-29 | 13G | Celldex Therapeutics, Inc. CLDX |
The Vanguard Group | 3,046,331 5.570% |
532,767 (+21.20%) |
Filing History |
| 2024-02-13 09:41 am Purchase |
2023-12-31 | 13G | Celldex Therapeutics, Inc. CLDX |
Polar Capital Holdings Plc | 3,135,871 5.730% |
3,135,871 (New Position) |
Filing History |
| 2024-02-09 08:50 am Sale |
2024-02-08 | 13G | Celldex Therapeutics, Inc. CLDX |
FMR CORP | 7,050,409 12.891% |
-14,565 (-0.21%) |
Filing History |
| 2024-02-08 10:11 am Purchase |
2023-12-29 | 13G | Celldex Therapeutics, Inc. CLDX |
WELLINGTON MANAGEMENT CO LLP | 6,476,561 11.840% |
1,695,064 (+35.45%) |
Filing History |